Form 4: RxSight Executive Ilya Goldshleger Exercises Options and Sells Shares

Ilya Goldshleger, Co-President and COO of RxSight, Inc., exercised stock options and sold shares of common stock on November 4, 2024, according to a Form 4 filing with the SEC.

Summary

• On November 4, 2024, Ilya Goldshleger, Co-President and Chief Operating Officer of RxSight, Inc. (RXST), exercised stock options to acquire 3,100 shares of common stock at a price of $15.08 per share.
• Following the exercise of options, Goldshleger sold 2,840 shares at a weighted average price of $50.9843, with prices ranging from $50.67 to $51.435.
• An additional 260 shares were sold at a weighted average price of $51.7372, with prices ranging from $51.68 to $51.805.
• After these transactions, Goldshleger directly owns 42,246 shares of RxSight common stock and indirectly owns 1,372 shares through a spouse.
• The sales were executed under a Rule 10b5-1 trading plan adopted on June 3, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't convey any explicit positive or negative sentiment about the company's performance or prospects.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions and provides insight into executive compensation and trading activity at RxSight, a company in the ophthalmic medical device industry. It's typical for executives to have pre-arranged trading plans to avoid accusations of insider trading.

Comparison to Industry Standards

• Executive compensation structures, including stock options and trading plans, are common across publicly traded companies, particularly in the medical device sector.
• Companies like Alcon, Johnson & Johnson Vision, and Bausch + Lomb also utilize similar equity-based compensation to align executive interests with shareholder value.
• The vesting schedule and exercise prices are typical for stock option grants in the industry.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the pre-planned nature of the sales mitigates concerns about insider information being used.

Key Dates